Active Ingredient: Olutasidenib
Olunib 150mg is a targeted therapy designed for the treatment of acute myeloid leukemia (AML) in patients with a specific isocitrate dehydrogenase-1 (IDH-1) mutation. This medication is intended for patients whose AML has either returned or has not responded to prior treatments. By inhibiting the IDH-1 enzyme, Olunib 150mg works to slow or stop the growth of leukemia cells, providing a potential option for patients with this challenging condition.
Indication:
- Acute Myeloid Leukemia (AML) with IDH-1 mutation (relapsed or refractory)
Mechanism of Action:
Olunib 150mg specifically targets the mutated IDH-1 enzyme, which is responsible for producing an abnormal protein that contributes to cancer cell growth. By inhibiting this enzyme, Olunib helps restore normal cell function and reduce the proliferation of leukemia cells.
Dosage Form: 150mg Tablets
Prescription Requirement:
This medicine is available only through a prescription, and patients must undergo testing to confirm the presence of the IDH-1 mutation before starting treatment.